KOSDAQBiotech & Pharma195940

HK inno.N

₩36,650▲ 0.14%2026-11-18 close
Market Cap
₩1T
Turnover
₩4.5B
Volume
120K
Shares out.
28.3M
PER
11.7×
PBR
0.7×
EPS
₩3,067
Dividend Yield
1.14%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩410 per share · Prices as of the 2026-11-18 close

01

Report overview

Keycap exports keep earnings firm as quarterly profit eases

HK inno.N's earnings rest on domestic Keycap prescriptions and rising export and royalty income, but quarterly operating profit has declined for three consecutive quarters since its 4Q25 peak, making the next quarterly results the key checkpoint.

  1. 1

    Operating profit and profit attributable to controlling shareholders each rose for three consecutive years from 2023 to 2025, and 2025 was the largest year of the 2022–2025 period, with sales at KRW 1.06 trillion.

  2. 2

    Third-quarter 2026 sales were KRW 260.4 billion, down 0.2% year on year, while operating profit was KRW 26 billion, up 0.6%; the company pointed to domestic Keycap shipment adjustments and an accounting change for price rebates.

  3. 3

    Keycap export sales reached KRW 4.5 billion in 2Q26, up 337.3% year on year, and royalty income is rising as overseas use grows, particularly in China.

  4. 4

    Quarterly operating profit peaked at KRW 40.1 billion in 4Q25 and declined for three straight quarters through 3Q26, while profit attributable to controlling shareholders recovered to KRW 19.6 billion in 3Q26.

02

Business structure

HK inno.N's business is split between prescription drugs (ETC) and health and beauty (H&B). In the first quarter of 2026, the ETC segment accounted for 92% of total sales and H&B for 8%.

The core product, the reflux disease drug Keycap (K-CAB), has held the top share of the domestic peptic ulcer drug market since its 2019 launch. Keycap is sold in 55 countries, including Korea, and has expanded into China, the United States, India and Latin America.

Second-quarter 2026 Keycap sales were KRW 49.3 billion, with domestic sales of KRW 44.8 billion down 6.9% year on year on the accounting change for usage-linked price rebates, and export sales of KRW 4.5 billion, up 337.3%. Higher overseas use, particularly in China, has also lifted royalty income.

IV fluid sales, produced at the Osong plant operating since 2022, rose 14% year on year to KRW 38.5 billion in 2Q26, with nutritional IV fluids a growing share of the mix. Other prescription lines include cardiovascular and diabetes products, and H&B includes Condition and Heotgae-su.

Keycap competes with other P-CAB drugs in Korea, and in China a vonoprazan-based rival is also on sale. The company filed a New Drug Application with the US FDA in January 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩260.8B₩25.9B9.9%
2025Q4₩291.9B₩40.1B13.7%
2026Q1₩258.7B₩33.2B12.8%
2026Q2₩267.2B₩30B11.2%
2026Q3₩260.4B₩26B10.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩846.5B₩52.5B₩38.1B6.2%3.3%54.9%
2023₩828.9B₩65.9B₩47.2B8.0%3.9%53.5%
2024₩897.1B₩88.2B₩61.6B9.8%4.9%51.0%
2025₩1.1T₩110.9B₩75.7B10.4%5.7%57.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual sales moved from KRW 846.5 billion in 2022 to KRW 828.9 billion in 2023 (down 2.1% year on year), then rose to KRW 897.1 billion in 2024 (up 8.2%) and KRW 1.06 trillion in 2025 (up 18.5%), growing for two consecutive years from 2024 to 2025.

Operating profit went from KRW 52.5 billion in 2022 to KRW 65.9 billion in 2023 (up 25.5%), KRW 88.2 billion in 2024 (up 33.8%) and KRW 110.9 billion in 2025 (up 25.7%), rising for three consecutive years from 2023 to 2025, while the operating margin widened from 6.2% in 2022 to 10.4% in 2025.

Profit attributable to controlling shareholders rose from KRW 38.1 billion in 2022 to KRW 75.7 billion in 2025, and net income including non-controlling interests was disclosed at the same amounts for each year.

Operating profit grew faster than sales in several years, which points to a larger contribution from higher-margin Keycap prescriptions and overseas royalties.

The debt-to-equity ratio, however, rose to 57.9% in 2025 from 51.0% in 2024, with total liabilities of KRW 768.5 billion and total equity of KRW 1.33 trillion at year-end 2025. Operating cash flow grew from KRW 58.6 billion in 2022 to KRW 162 billion in 2025. The quarterly path diverged from the annual trend.

Sales rose from KRW 260.8 billion in 3Q25 to KRW 291.9 billion in 4Q25 (up 11.9% quarter on quarter) before falling to KRW 258.7 billion in 1Q26 (down 11.4%), then KRW 267.2 billion in 2Q26 (up 3.3%) and KRW 260.4 billion in 3Q26 (down 2.6%).

Operating profit peaked at KRW 40.1 billion in 4Q25 (up 55.0% quarter on quarter), then fell to KRW 33.2 billion, KRW 30 billion and KRW 26 billion across 1Q26 to 3Q26, declining for three consecutive quarters. Operating profit was up 30.8% year on year in 1Q26 and up 0.6% in 3Q26.

Profit attributable to controlling shareholders fell to KRW 13.7 billion in 2Q26 (down 47.3% quarter on quarter) and recovered to KRW 19.6 billion in 3Q26 (up 43.3%). The last four quarters, from 4Q25 to 3Q26, total KRW 86.9 billion in profit attributable to controlling shareholders.

05

Industry analysis

Keycap belongs to the P-CAB class (potassium-competitive acid blockers), which is positioned as an alternative to proton pump inhibitors, and competition among P-CAB drugs in Korea is cited as a market risk.

An April 2026 report noted that Keycap's first-quarter domestic sales held steady despite concerns about intensifying competition.

In the United States, Samsung Securities said in a June 2025 report that the resolution of regulatory exclusivity uncertainty for a competing product reduced concerns about early generic competition for Keycap.

In China, whether products can avoid volume-based procurement (VBP) is the key question, and Keycap is sold alongside a vonoprazan-based rival. The IV fluid market has been normalizing as a strike by medical staff eased and hospital demand recovered.

Among Korean pharmaceutical companies, HK inno.N became the eighth to pass KRW 1 trillion in annual sales, with 2025 sales of KRW 1.06 trillion. Keycap prescriptions outside hospitals reached KRW 61.5 billion in 2Q26, up 15.4% year on year, a direct gauge of demand.

The company says it aims to keep improving profitability through domestic prescription growth and overseas expansion.

06

Outlook

The company says it aims to keep improving profitability through domestic Keycap prescription growth and overseas expansion. Keycap prescriptions outside hospitals rose 16.5% year on year in 3Q26, and cumulative operating profit for the first three quarters of 2026 was up 26.1% year on year.

The company filed its New Drug Application with the US FDA in January 2026, and in an October 2026 report Shinhan Securities pointed to a US approval in the first half of 2027 as a possible share-price catalyst. In the same report, Shinhan Securities noted that inventory adjustments reduced Keycap shipments in 3Q26.

In an April 2026 report, DS Investment & Securities estimated initial US royalty income of about KRW 5.5 billion starting in 2027 if Keycap settles in the US market.

The same report noted that a European partnership was nearing completion, and DS Investment & Securities projected 2026 IV fluid sales could expand to KRW 149.3 billion. These are broker estimates rather than company guidance.

With quarterly operating profit declining through 3Q26, the trajectory from 4Q26 onward and the US approval timeline are the central variables.

07

Valuation

PER
11.7×
PBR
0.7×
ROE
6.5%
EPS
₩3,067
BPS
₩48,343
Dividend per share
₩410

Market capitalization sits below total equity of KRW 1.33 trillion at year-end 2025, meaning the share price trades below book value per share.

Operating profit rose from KRW 52.5 billion in 2022 to KRW 110.9 billion in 2025, and profit attributable to controlling shareholders grew from KRW 38.1 billion to KRW 75.7 billion over the same period, so earnings have grown faster than the asset base.

In an October 2026 report, Shinhan Securities lowered its target price from KRW 68,000 to KRW 59,000 and kept a Buy rating.

In a July 2026 company brief, iM Securities maintained its fair value of KRW 60,000 and its rating; its valuation applied the average EV/EBITDA of major Korean pharmaceutical companies based on earnings over the next twelve months.

Both targets reflect each firm's earnings assumptions and multiples, so the gap to the share price depends on those inputs. Profit attributable to controlling shareholders over the last four quarters totals KRW 86.9 billion, which forms the earnings base for these comparisons.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Overseas Keycap exports and royalties expanding

Keycap export sales reached KRW 4.5 billion in 2Q26, up 337.3% year on year, and in China all three indications now carry reimbursement, which is widening use. Cumulative operating profit for the first three quarters of 2026 rose 26.1% year on year, showing overseas royalties supporting earnings.

Shinhan Securities, in an October 2026 report, cited a US approval in the first half of 2027 and a European partnership as momentum factors for the share price.

IV fluids and higher-margin mix

IV fluid sales recovered after a strike by medical staff eased, reaching KRW 38.5 billion in 2Q26, up 14% year on year. Nutritional IV fluids, which carry higher margins, are a growing share each year, and that mix is improving profitability.

DS Investment & Securities, in an April 2026 report, projected IV fluid sales could expand to KRW 149.3 billion for the year.

Wider operating margin and larger profit base

The operating margin widened from 6.2% in 2022 to 10.4% in 2025, and operating profit grew from KRW 52.5 billion to KRW 110.9 billion over the same period. Profit attributable to controlling shareholders rose for three consecutive years from 2023 to 2025.

Total equity was KRW 1.33 trillion at year-end 2025, and profit attributable to controlling shareholders over the last four quarters totals KRW 86.9 billion.

09

Bear factors

Sales decline and accounting effects

Third-quarter 2026 sales were KRW 260.4 billion, down 0.2% year on year, and domestic Keycap sales fell 6.9% in 2Q26. The accounting change for usage-linked price rebates is seen as a temporary effect, but quarterly sales have stayed near KRW 260 billion since the 4Q25 peak. How long the accounting effect lasts will shape the sales trend.

Three straight quarterly declines in operating profit

Quarterly operating profit fell from KRW 40.1 billion in 4Q25 to KRW 33.2 billion in 1Q26, KRW 30 billion in 2Q26 and KRW 26 billion in 3Q26, declining for three consecutive quarters.

In an October 2026 report, Shinhan Securities said inventory adjustments reduced Keycap shipments, and that China royalties could fall short of the roughly KRW 4 billion level it had previously expected.

Domestic competition and China exposure

Concerns over intensifying competition among P-CAB drugs in Korea were raised in an April 2026 report. In China, anti-corruption measures in the medical sector have weighed on sales, and royalties may come in below expectations. Whether Keycap can avoid volume-based procurement in China is seen as a key factor for its medium-term share.

10

Risk factors

Regulatory and approval timing

The timing of a US launch depends on the FDA review of the New Drug Application filed in January 2026. Shinhan Securities cited a delay in a European distribution agreement as a factor in its October 2026 target cut. A delayed approval or a failed agreement could change the royalty assumptions.

Accounting and pricing variables

The accounting treatment of usage-linked price rebates and domestic Keycap shipment adjustments directly affected 2Q26 and 3Q26 sales. Changes to domestic pricing rules or rebate amounts could alter how sales are recognized again. Quarterly results need to be read with these items separated out.

Concentration in overseas royalties

Overseas royalties depend heavily on prescription trends and policy changes in China. Anti-corruption measures in China's medical sector and the VBP system could affect royalty levels. As overseas income grows as a share of earnings, policy shifts in a single country carry more weight for total profit.

11

What to watch next

  1. Around February 2027 (expected)

    The 4Q26 preliminary results will show whether quarterly operating profit, which has declined for three straight quarters since the 4Q25 peak, rebounds.

  2. By March 31, 2027

    The deadline for the 2026 annual report, where the operating margin (10.4% in 2025) and the debt-to-equity ratio (57.9% in 2025) can be checked against audited figures.

  3. First half of 2027

    The US approval decision for Keycap, which Shinhan Securities cited in October 2026 as a share-price momentum factor and which determines when US royalty income could begin.

  4. Late April 2027 (expected)

    The 1Q27 preliminary results will show whether quarterly operating profit recovers from the KRW 26 billion level in 3Q26 and whether export growth for Keycap continues.

12

Overall view

HK inno.N's sales, operating profit and profit attributable to controlling shareholders each rose over 2022 to 2025, and its operating margin widened from 6.2% to 10.4%. Domestic Keycap prescriptions, overseas exports and royalties support earnings, and IV fluids are growing.

However, quarterly operating profit has declined for three straight quarters through 3Q26, and 3Q26 sales were affected by an accounting change and shipment adjustments.

Shinhan Securities (October 2026) and iM Securities (July 2026) presented target prices of KRW 59,000 and KRW 60,000, respectively, and both depend on US approval and overseas royalty assumptions. The debt-to-equity ratio rose to 57.9% in 2025, which also warrants monitoring.

The next checkpoints are the 4Q26 preliminary results and the 2026 annual report, and the US approval outcome is likely to determine the direction of overseas royalty expectations.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.investing.com
  2. ebn.co.kr
  3. kr.investing.com
  4. dailian.co.kr
  5. file.alphasquare.co.kr
  6. mt.co.kr
  7. news.nate.com
  8. m.news.nate.com
  9. m.news.nate.com
  10. news.nate.com
  11. news.nate.com
  12. news.nate.com
  13. news.nate.com
  14. news.nate.com
  15. newspim.com
  16. newspim.com
  17. newspim.com
  18. supple.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis